Print page
Email page
Download PDF
« Previous Release | Next Release »
CLEARWATER, Fla., Oct 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Lincare Holdings Inc. (Nasdaq: LNCR), a leading provider of oxygen and other respiratory therapy services delivered to patients in the home, today announced financial results for the three and nine months ended September 30, 2008.
For the quarter ended September 30, 2008, revenues were $405.7 million compared with revenues of $408.2 million for the third quarter of 2007. The Company estimates that the change in net revenues was comprised of approximately 5% internal growth, offset by Medicare price reductions of approximately 6% taking effect in 2008. Net income for the quarter ended September 30, 2008, was $55.8 million compared to net income of $58.6 million for the third quarter of 2007. Diluted earnings per share were $0.76 for the quarter ended September 30, 2008, compared with $0.66 diluted earnings per share for the comparable prior year period.
Revenues for the nine months ended September 30, 2008, were $1.249 billion, a 6% increase over revenues of $1.184 billion for the comparable period in 2007. The Company estimates that the increase in net revenues was comprised of approximately 10% internal growth, partially offset by Medicare price reductions of approximately 5% taking effect in 2008. Net income for the nine months ended September 30, 2008, was $179.0 million compared to net income of $168.5 million for the first nine months of 2007. Diluted earnings per share were $2.38 for the nine months ended September 30, 2008, compared with $1.89 diluted earnings per share for the comparable period last year.
As previously reported, revenues and earnings were impacted in the second and third quarters of 2008 by a change in ordering patterns for certain inhalation drugs by customers concerned about the potential loss of Medicare coverage of these drugs. In April of this year, the Durable Medical Equipment Medicare Administrative Contractors ("DME MACs") issued a revision of the Nebulizer Local Coverage Determination ("LCD") that would have effectively eliminated Medicare reimbursement and patient access to these medications as of July 1, 2008. In response to this potential loss of access, a significant number of the Company's customers placed orders in June to receive a 90-day shipment of these drugs rather than a 30-day shipment. The net effect of this change in ordering patterns was to accelerate approximately $18.9 million of revenues in the second quarter that would otherwise have been expected to occur in the third quarter. The DME MACs subsequently announced a delay in the implementation of the LCD until November 1, 2008.
Lincare added 10 new operating centers during the third quarter derived from internal development. During the first nine months of 2008, Lincare opened 30 new locations, expanding the total number of locations to 1,049 at September 30, 2008. Lincare also completed acquisitions of two small pharmacy operations during the third quarter.
John P. Byrnes, Lincare's Chief Executive Officer, said, "We are pleased with Lincare's operating and financial performance in the first nine months of 2008. We continue to demonstrate the ability to expand our market share and drive strong operating results despite Medicare price cuts of more than $55 million so far this year. We have been consistently able to generate internal revenue gains of about twice the underlying growth in the market for our services while containing the growth of our operating and overhead expenses. Our financial position and liquidity remain strong and we achieved significant operating cash flows in the first nine months of 2008."
Lincare generated $322.1 million of cash from operating activities during the first nine months of 2008. Investments of cash during the nine-month period included $95.0 million in net capital expenditures and $6.1 million in business acquisition expenditures. As of September 30, 2008, total debt outstanding was $622.7 million, cash and cash equivalents were $32.9 million and long-term investments were $92.9 million.
Lincare, headquartered in Clearwater, Florida, is one of the nation's largest providers of oxygen and other respiratory therapy services to patients in the home. The Company provides services and equipment to approximately 700,000 customers in 48 states.
Statements in this release concerning future results, performance or expectations are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All forward-looking statements included in this document are based upon information available to Lincare as of the date hereof and Lincare assumes no obligation to update any such forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause Lincare's actual results, levels of activity, performance or achievements to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statements. In some cases, forward-looking statements that involve risks and uncertainties contain terminology such as "may," "will," "should," "could," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or variations of these terms or other comparable terminology.
Key factors that have an impact on Lincare's ability to attain any estimates contained in this release include potential reductions in reimbursement rates by government and other third party payors, changes in reimbursement policies, the demand for Lincare's products and services, the availability of appropriate acquisition candidates and Lincare's ability to successfully complete and integrate acquisitions, efficient operation of Lincare's existing and future operating facilities, regulation and/or regulatory action affecting Lincare or its business, economic and competitive conditions, access to borrowed and/or equity capital on favorable terms and other risks described in the filings of Lincare with the Securities and Exchange Commission.
In developing its forward-looking statements, Lincare has made certain assumptions relating to reimbursement rates and policies, internal growth and acquisitions and the outcome of various legal and regulatory proceedings. If the assumptions used by Lincare differ materially from what actually occurs, then actual results could vary significantly from the performance projected in the forward-looking statements. Lincare is under no duty to update any of the forward-looking statements after the date of this announcement.
LINCARE HOLDINGS INC.
Financial Summary
(Unaudited)
(In thousands, except share and per share data)
For the three months ended
September 30, September 30,
2008 2007
Net revenues $405,677 $408,152
Costs and expenses:
Costs of goods and services 94,969 101,398
Operating expenses 100,508 91,458
Selling, general and administrative
expenses 82,165 80,128
Bad debt expense 6,085 6,122
Depreciation and amortization
expense 29,015 29,957
Operating income 92,935 99,089
Interest expense, net 4,076 4,339
Income before income taxes 88,859 94,750
Income taxes 33,073 36,111
Net income $55,786 $58,639
Basic earnings per common share $0.76 $0.69
Diluted earnings per common share $0.76 $0.66
Weighted average number of common
shares outstanding 73,005,817 84,562,220
Weighted average number of common
shares and common share equivalents
outstanding 73,434,927 90,551,077
For the nine months ended
September 30, September 30,
2008 2007
Net revenues $1,249,488 $1,183,694
Costs and expenses:
Costs of goods and services 302,362 289,494
Operating expenses 294,442 272,939
Selling, general and administrative
expenses 243,708 236,190
Bad debt expense 18,742 17,755
Depreciation and amortization
expense 88,618 83,694
Operating income 301,616 283,622
Interest expense, net 14,027 13,945
Income before income taxes 287,589 269,677
Income taxes 108,550 101,188
Net income $179,039 $168,489
Basic earnings per common share $2.46 $1.98
Diluted earnings per common share $2.38 $1.89
Weighted average number of common
shares outstanding 72,902,841 85,033,782
Weighted average number of common
shares and common share equivalents
outstanding 76,345,503 91,392,442
LINCARE HOLDINGS INC.
Selected Balance Sheet Data
(Unaudited)
(In thousands)
September 30, December 31,
2008 2007
Cash and Investments $125,816 $149,957
Accounts Receivable, Net 198,915 198,918
Current Assets 269,134 366,211
Total Assets 1,934,492 1,928,364
Current Liabilities 246,055 438,474
Total Debt 622,724 838,207
Stockholders' Equity 896,688 733,788
SOURCE Lincare Holdings Inc.
http://www.lincare.com
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX